Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An effective vaccine against infection with human immunodeficiency virus type 1 (HIV-1) is thought likely to require both a humoral and a CTL immune response. A non-replicating adenovirus vector system has been developed that can induce both a humoral and CTL response to HIV-1 envelope in mice. It is demonstrated that the stimulatory tat/rev 5' splice-donor site sequence is required for efficient expression of HIV-1 env by this adenovirus vector system. rev can be provided bicistronically or in trans to result in good expression of env in vitro. A humoral immune response was detected after two immunizations with a bicistronic recombinant adenovirus (RAd142). The response was dose dependent, 5x10(7) p.f.u. inducing a response in some, but not all, animals and 1x10(8) p.f.u. giving a consistent antibody response. However, CTLs were induced by the lower dose of virus and after only one immunization with the higher dose. A positive CTL response was also seen consistently when the two monocistronic adenoviruses (RAd501 expressing env and RAd46 expressing rev) were given together, although two immunizations were required to give approximately the same level of response as seen with the bicistronic virus. RAd501 on its own also gave a low CTL response when two immunizations were given. It is suggested that a lower level of env expression is required to produce a CTL response than a humoral response and that this nonreplicating adenovirus vector is a good system for inducing CTL.

Original publication




Journal article


J Gen Virol

Publication Date



80 ( Pt 10)


2621 - 2628


AIDS Vaccines, Adenoviruses, Human, Animals, Antibody Formation, Binding Sites, Cell Line, Transformed, Cells, Cultured, Gene Products, env, Gene Products, rev, Gene Products, tat, Genetic Vectors, HIV Antibodies, HIV Antigens, HIV-1, Humans, Mice, Mice, Inbred BALB C, RNA Splicing, Recombinant Fusion Proteins, Recombination, Genetic, T-Lymphocytes, Cytotoxic, Vaccination, Virus Replication, rev Gene Products, Human Immunodeficiency Virus, tat Gene Products, Human Immunodeficiency Virus